State of Wyoming boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 293.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,335 shares of the biopharmaceutical company's stock after purchasing an additional 16,652 shares during the quarter. State of Wyoming's holdings in Pfizer were worth $593,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at $27,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter valued at $31,000. Finally, Bernard Wealth Management Corp. purchased a new stake in shares of Pfizer in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Pfizer Stock Up 2.2%
Shares of NYSE:PFE traded up $0.51 during trading on Tuesday, reaching $23.51. The stock had a trading volume of 56,982,321 shares, compared to its average volume of 41,026,680. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm's 50-day simple moving average is $23.56 and its 200 day simple moving average is $25.27.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue was down 7.8% compared to the same quarter last year. During the same period last year, the business earned $0.82 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.32%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is currently 124.64%.
Wall Street Analyst Weigh In
Several research analysts recently commented on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $29.17.
Read Our Latest Stock Report on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
